Impact of Natalizumab on Patient-Reported Outcomes in a Clinical Practice Setting

Siddhesh Kamat, Krithika Rajagopalan, Judith Stephenson () and Sonalee Agarwal

The Patient: Patient-Centered Outcomes Research, 2009, vol. 2, issue 2, 105-112

Abstract: Objective: To assess multiple sclerosis (MS) patients’ experience with natalizumab (TYSABRI®, Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.) in a clinical practice setting. Methods: MS patients who were enrolled in the TOUCH (TYSABRI® Outreach Unified Commitment to Health) prescribing program and who had received their third natalizumab infusion participated in this study. Patient-reported measures included an overall quality-of-life (QOL) assessment, an adapted version of the Multiple Sclerosis Impact Scale-29 (MSIS-29), and pre-/post-disease level and functional status scores. MSIS-29 responses were modified to measure patient-perceived change since initiating natalizumab. Paired t-tests assessed pre-/post-changes in disease level and functional status, where negative change indicated improvement. Results: Results from 451 patients in this study indicated that 73% were female and, on average, were diagnosed with MS >11 years previously. Almost all (96%) patients had used one or more MS drugs prior to natalizumab initiation. After receiving natalizumab, 97% of all patients reported an improvement or remained stable in their overall QOL. Despite the short treatment duration, there were significant improvements (mean ± SD change) in disease level (−0.26 ± 0.99, paired t-test=5.47; p > 0.001) and functional status (−0.33 ± 0.73, paired t-test= 9.40; p > 0.001) scores. More than 80% of patients reported an improvement in one or more MSIS-29 physical items. The physical item on the adapted MSIS-29 with the highest reported improvement (58%) was ‘the ability to do physically demanding tasks’. The physical item with the lowest reported improvement (32%) was ‘problems using transport’. Conclusion: Overall, the experiences of MS patients with natalizumab were positive in a clinical practice setting. Patients reported improvements in overall QOL, ambulation and functional status as early as after three natalizumab infusions. While preliminary, these early results are suggestive of a beneficial effect of natalizumab in patients with MS and warrant further long-term investigation of the impact of this treatment on patient outcomes. Copyright Adis Data Information BV 2009

Date: 2009
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/01312067-200902020-00006 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:2:y:2009:i:2:p:105-112

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.2165/01312067-200902020-00006

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().